New Australian biosimilar guidance takes up WHO naming proposal
This article was originally published in Scrip
Executive Summary
Generic companies planning to market biosimilar medicines in Australia will have to apply to the World Health Organization for a unique INN identifying code, and all biosimilars will have to have a clearly distinguishable trade name, according to guidance just published by the Therapeutic Goods Administration (TGA).
You may also be interested in...
Australia Revives Debate Over Unique Suffixes For Biologic Medicines
The Australian medicines agency has launched a public consultation on whether specific naming requirements should be applied to biologicals and their biosimilar versions. Among the options are the use of bar codes and suffixes to ensure individual products can be identified for traceability and pharmacovigilance purposes.
Australia Revives Debate Over Unique Suffixes For Biologic Medicines
The Australian medicines agency has launched a public consultation on whether specific naming requirements should be applied to biologicals and their biosimilar versions. Among the options are the use of bar codes and suffixes to ensure individual products can be identified for traceability and pharmacovigilance purposes.
‘Close The R&D Gap’ Between EU & Other Regions, EFPIA Tells Lawmakers
As EU legislators begin their discussion of the EU pharmaceutical overhaul, EFPIA has issued its formal response to the proposals, with a focus on topics such as unmet medical need, environmental risk assessments and drug shortages.